Investigation of HER2 overexpression in non-small cell lung cancer

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 3061-3066

  Ugocsai, Katalin ^a   Mándoky, László ^b   Tiszlavicz, László ^a   Molnár, Joseph ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

FISH; HER2; Immunohistochemistry; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVITY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TUMOR CELL;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 22944467837     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T, Chen MH and Perng RP: Correlation between intrinsic chemoresistence and HER2 gene expression, p53 mutations and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 56: 206-209, 1996.
2. Gusterson BA, Gelber RD, Goldhirsh A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R and Reed R: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10(7): 1049-1056, 1992.
3. Tal M, Wetzler M and Josefberg Z: Sporadic amplification of HER2 protooncogene in adenocarcinomas of various tissues. Cancer Res 48: 1517-1520, 1998.
4. Brabender J, Danenberg DK, Metzger R, Schneider MP, Park JM, Salonga D, Hölscher HA and Danenberg VP: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7(7): 1850, 2003.
5. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF: Studies of the HER2 proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
6. Pauletti G, Godolphin W, Press MF and Slamon DJ: Detection and quantification of HER2 gene amplification in human breast cancer archival material using fluorescence in situ hybridisation. Oncogene 13: 63-72, 1996.
7. Slamon DJ, Leyland-Jones B and Shack S: Addition of Herceptin (humanized anti HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial. Proc Am Soc Clin Oncol 17: 98a, 1998 (abstr 377).
8. Ross JS and McKenna BJ: The HER2 oncogene in tumors of the gastrointestinal tract. Cancer Invest 19: 554-568, 2001.
9. Ukita Y, Kato M and Terada T: Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER2) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization and immunohistochemistry. J Hepatol 36: 780-785, 2002.
10. Mandoky L, Geczi L, Bodrogi I, Toth J and Bak M: Expression of HER2 in testicular tumors. Anticancer Res 23(4): 3447-3451, 2003.
11. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA and Horowitz IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21: 283-290, 2003.
12. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ and Parham GP: Overexpression of HER2 in uterine serous papillary cancer. Clin Cancer Res 8: 1271-1279, 2002.
13. Latif Z, Watters AD, Dunn I, Grigor KM, Underwood MA and Bartlett JM: HER2 overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 89: 1305-1309, 2003.
14. Fossa A, Lilleby W, Fossa SD, Gaudernack G, Torlakovic G and Berner A: Independent prognostic significance of HER2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy. Int J Cancer 99: 100-105, 2002.
15. Scheurle D, Jahanzeb M, Aronsohn RS, Watzek L and Narayanan R: HER2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test. Anticancer Res 20: 2091-2096, 2000.
16. Tan D, Deeb G, Wang J, Slocum HK, Winston J, Wiseman S, Beck A, Sait S, Anderson T, Nwogu C, Ramnath N and Loewen G: HER2 protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn Mol Pathol 12(4): 201-211, 2003.
17. Kern JA, Slebos RJ, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D and Schwartz DA: C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93: 516-520, 1994.
18. Pfeiffer P, Clausen PP, Andersen K and Rose C: Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER2 in patients with systematically untreated non-small cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 74: 86-91, 1996.
19. Bunn PA Jr, Helfrich B, Soriano AF, Franklin WF, Varella-Garcia M, Hirsch FR, Baron A, Zeng C and Chan DC: Expression of HER2 in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 7: 3239-3250, 2001.
20. Andre F, Le Chevalier T and Soria CJ: Her2-neu: a target in lung cancer? Ann Oncology 15: 3-4, 2004.
21. Cox G, Vyberg M, Melgaard B, Askaa J, Oster A and O'Byrne KJ: Herceptest: HER2 expression and gene amplification in non-small cell lung cancer. Int J Cancer 92: 480-483, 2001.
22. Mountain CF: A new international staging system for lung cancer. Chest 89: 225-233, 1986.
23. World Health Organisation: The World Health Organisation histological typing of lung cancer. Am J Clin Pathol 77: 123-136, 1982.
24. Perez AE, Roche CP, Jenkins BR, Carol A, Reynolds AC, Halling CK, Ingle NJ and Wold EL: HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77: 148-154, 2002.
25. Salomon DS, Brandt R, Ciardello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19(3): 183-232, 1995.
26. Ciardiello F: Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60(1): 25-32, 2000.
27. Raymond E, Faivre S and Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60(1): 15-23, 2000.
28. Brabender J, Enberg KD, Metzger R, Schneider PM, Park J, Ga D, Holscher AH and Danenberg PV: Epidermal growth factor receptor and HER2 mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7: 1850-1855, 2001.
29. Lai WW, Chen FF, Wu MH, Chow NH, Su WC, Ma MC, Su PF, Chen H, Lin MY and Tseng YL: Immunhistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer. Ann Thorac Surg 72: 1868-1876, 2001.
30. Selvaggi G, Scagliotti VG, Torri V, Novello S, Leonardo E, Cappia S, Mossetti C, Ardissone F, Lausi P and Borasio P: HER2 overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival. Cancer 94(10): 2669-2674, 2002.
31. Slamon DJ, Godolphin W, Jones LA, Wong SO, Keith DE, Lewis WJ, Sturt SO, Udove J, Ullrich A and Press MF: Studies of the HER/2 proto-oncogene in human breast and ovarian cancer. Science 244: 707-182, 1987.
32. Jacobs TW, Gown AM, Yaziji H, Barnes MJ and Schnitt SJ: Specificity of Hercept Test in determining the HER2 status of breast cancers using the United States Food and Drug Administration approved scoring system. J Clin Oncol 17: 1983-1987, 1999.
33. Pellegrini C, Falleni M, Marchetti A, Cassani B, Miozzo M, Buttitta F, Roncalli M, Coggi G and Bosari S: HER2 alterations in non-small cell lung cancer. Clin Cancer Res 9: 3645-3652, 2003.
34. Schneider PM, Hung M-C, Chiocca SM, Manning J, Zhao X, Fang K and Roth JA: Differential expression of the c-erbB2 gene in human small cell and non small cell lung cancer. Cancer Res 50: 5184-5191, 1989.
35. Cobleigh MA, Vogel CL, Tripathy D, Robert JN, Scholl S, Fehrenbacher L, Wolter MJ, Paton V, Shak S, Lieberman G and Slamon JD: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999.
36. Rosell R: Toward customized Trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers. J Clin Oncol 22: 1171-1173, 2004
37. Langer CJ, Adak S, Thor A, Vangel M and Johnson D: Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C) and trastuzumab (T) in HER2(+) advanced non-small cell lung cancer (NSCLC): early analysis of E2598. Am Soc Clin Oncol 20: 315a A-1257, 2001.
38. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P and Hirsh V: Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15: 19-27, 2004.